Shionogi & Co., Ltd. – Q2 Financial Summary [IFRS] (Consolidated)

Overview of Results

Shionogi & Co., Ltd. announced its Q2 financial summary for the fiscal year ending March 2027, recording revenue of 350,377 million yen, operating income of 115,244 million yen, and interim profit attributable to owners of the parent of 119,546 million yen. Year-over-year increases of 64.5% in revenue, 55.8% in operating income, and 44.0% in interim profit were achieved. Key contributors include impacts from business combinations such as the transfer of the edaravone business, equity-method investment gains related to ViiV Healthcare, and expanded product sales in North America and Europe. The full-year forecast was also revised upward, with revenue expected at 720,000 million yen, operating income at 230,000 million yen, and net income of 212,500 million yen.

Dividends, Financial Policy and Outlook

With the upward revision to an interim dividend of 40 yen and a year-end dividend of 46 yen, the annual dividend is 86 yen, an increase of 15 yen year-over-year and the 14th consecutive year of dividend increases anticipated. The company intends to prioritize returning the benefits of growth investments to shareholders, strengthening cash generation through the effects of business combinations and acquisitions after October 2026 while continuing to prioritize development investments. This earnings release includes finalized provisional accounting for multiple business combinations, with goodwill and intangible asset valuations impacting the financials.